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Leukemic cells from patients with acute myeloid leukemia (AML)' and chronic
myeloid leukemia (CML) secrete plasminogen activators either of the urokinase
(uPA) or the tissue (tPA) type, and in a recent study (1) it has been shown that
the species of enzyme released by AML cells predicted the response to chemo-
therapy . Patients whose cells secreted only tPA failed to respond to combination
chemotherapy, whereas those whose cells released uPA alone or a combination
of uPA and tPA could be induced to achieve remission .
Anumber of other functional properties of myeloid leukemic clonogenic cells
have also been shown to correlate with the response of the individual to induction
chemotherapy (2-4) . Generally speaking, these properties are those that char-
acterize normal hemopoietic cellsat various stages of differentiation and matura-
tion . Poor responses are usually seen when leukemic cells display features of the
early progenitor phenotype (3, 5-7) . It seemed likely, therefore, that secretion
of the two species of plasminogen activator by hemopoietic cells might also be
differentiation linked and that the association between uPA secretion and favor-
able therapeutic outcome reflected the tendency of early cells to release tPA,
whereas later cells secrete uPA .
In this paper we record the results ofa series of experiments in which normal
human bone marrow was fractionated by equilibrium density gradient centrif-
ugation (8) into cells at different stages of differentiation (7, 9, 10) . Correlation
ofcell density, growth characteristics in semisolid agar, and plasminogenactivator
release supports the notion that the species of plasminogen activator synthesized
is a function of differentiation/maturation .
Materials and Methods
Bone Marrow Cells.
￿
Bone marrow aspirates from the posterior iliac crestwere obtained
from healthy donors with informed consent and the approval of the ethical practices
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committee of the Royal Free Hospital. Leucocyte-rich supernatants were obtained by
sedimentation at unit gravity as previously described (6).
Cell Separation by Equilibrium Density Centrifugation.
￿
Cells were separated on the basis
of differences in buoyant density in continuous Ficoll/Isopaque gradients. The method is
essentially that of Loos and Roos (8), in which high- and low-density solutions consisting
of different concentrations of Ficoll (Pharmacia Fine Chemicals, Uppsala, Sweden) and
Isopaque (Nyegaard and Co., Lidingo, Sweden) in Tris-HCl and Ringer's solution are
used to generate the gradients. The heavy and light solutions used for these experiments
had osmolalities of 285 ± 3 mmol/kg and were pH 7.4. The density range used was ^-1 .04
to 1 .09 g/cm3. Density gradients of 15 ± 0 .5 ml were generated by continuous mixing of
low- and high-density solutions in a gradient maker. This was dispensed into 14-mm
diameter polycarbonate tubes (MSE Scientific Instruments, Crawley, Sussex, United
Kingdom) through a 0.22-pin acrodisc filter. Cells from bone marrow leucocyte-rich
supernatants were washed in supplemented McCoy's 5A medium (see below) to remove
plasma, were recovered by centrifugation at 400 g for 6 min, and were then resuspended
in low-density solution (0.5 to 0 .8 ml) and gently layered on top of the gradient. An
aliquot of these cells was retained so that the unseparated cell population could be
cultured. Gradients were loaded with ^-7 X 107 nucleated cells (loads in excess of 108 cells
decrease the resolution of the separation).
The preparation of the cells, generation, and loading of the gradient all took place at
room temperature (-22°C). Gradients were spun at 2,600 g for 25 min at 22°C.
Preliminary experiments indicated that 25 min was sufficient time for equilibrium to be
reached. 12-13 fractions were collected by gentle aspiration with syringes and filling
tubes (Kwills; S & N Everet Ltd., London, United Kingdom).
The density ofeach fraction was calculated from the refractive index using a calibration
curve obtained by weighing known volumes of various mixtures of heavy and light
solutions at 22 °C and then relating this to refractive index. Refractive index of this
material has a linear relationship to density. The gradients were linear over the major
part of the range and density increments of the fractions were ^-0.004 g/cm8. Cells were
recovered from the fractions by dilution with 4 ml of supplemented McCoy's 5A tissue
culture medium containing 15% FCS, followed by centrifugation (400 g, 6 min) and
resuspension in appropriate medium (McCoy's 5A for granulocyte/macrophage (CFUgm)
CFU cultures, Iscove's modified Dulbecco's medium for granulocyte/eryth-
rocyte/megakaryocyte/macrophage (CFUgemm) CFU cultures, RPMI 1640 containing
3% FCS for plasminogen activator assays). For morphological analyses cells were sus-
pended in PBS, pH 6 .8, supplemented with 10% FCS and were recovered by cytosedi-
mentation at unit gravity and either stained with May-Grunewald-Giemsa or cytochemi-
cally for nonspecific or chloroacetate esterase as previously described (11).
Culture Methods for CFUgm and CFUgemm.
￿
CFUgm were cultured using the double-
layer agar technique of Pike and Robinson (12). Cells from the various density fractions
were cultured' in 0.3% agar overlayers. Not all fractions were cultured at the same cell
density, as fractions that were expected to produce large numbers of colonies were diluted
to avoid crowding and overlap of colony growth. The range of cell densities cultured was
from ^-I X 104 to 2 X 105 cells per overlayer. Feeder layers supplying the growth stimulus,
granulocyte/macrophage colony-stimulating activity (gmCSA) were prepared containing
106 peripheral blood leucocytes per milliliter. Since we have previously demonstrated (11)
that feeder layer activity has an effect on estimation of buoyant density distribution of
CFUgm (higher levels of gmCSA recruit additional low-density progenitors to form
colonies), each experiment was performed in triplicate using feeder layers from three
different donors and the results were those obtained on the feeder layer stimulating the
largest number of clones. Previous studies (13) in our laboratory have shown that this
best-of-three approach ensures maximal stimulation of clone formation (13) . Cultures
were incubated at 37 ° C in a fully humidified atmosphere of 5% C02 in air for 7 d.
For caseinolytic plaque assays, replicate cultures were made containing 105 low-density
(^-1 .063 g/cm8) bone marrow cells and were examined at various time intervals. Gels wereWILSON AND FRANCIS
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cut in half and removed from the culture dish into a bath containing PBS, pH 6.8. The
half gels were then placed, overlayer down, on to a microscope slide. After removal of
the feeder layer, the overlayer gel was dehydrated by covering it with filter paper
(Whatman 50 hardened; Whatman Ltd., Maidstone, Kent, United Kingdom) and addi-
tional absorbent paper weighted down with a glass sheet. After 10-15 min, the paper
layers were carefully removed leaving a thin agar film on the slide. This was not allowed
to dry before coating with the agar casein mixture for the caseinolytic plaque assay (see
below).
The culture method for CFUgemm is a modification of that of Fauser and Messner,
(14) the details of which have been published elsewhere (9). 1-ml cultures containing 104
to 2 X 105 cells in Iscove's modified Dulbecco's medium (Gibco, Paisley, Scotland) with 5
X 10-5 M 2-ME, 30% human citrated plasma, and 0.25% agar were prepared in 35-mm
dishes (Falcon Labware, Oxnard, CA). The growth stimuli were erythropoietin and
conditioned medium obtained by the method of Aye et al. (15) from PHA-stimulated
leucocytes (PHA-LCM). PHA-LCM was used at 2.5% (vol/vol), the optimal concentration
for the batch used, and erythropoietin was used at 1 U/ml. Cultures were scored after 14
d of incubation .
Agar gels were removed from the dishes, dehydrated using Whatman No. 50 filter
paper as described above, and were air dried and stained from hemoglobin-containing
cell using O-dianisidine (Helena Laboratories, Beaumont, TX) as previously described
(16). Mixed colonies containing an erythrocytic component are easily identifiable by the
deep russet colour of hemoglobin containing O-dianisidine-positive cells.
Cytochemical Staining.
￿
In situ staining of granulocyte/macrophage colonies for nonspe-
cific and chloroacetate esterase was performed as previously described (17). The same
technique was also applied to the caseinolytic plaque assay preparations in which cells
were suspended directly in the RPMI agar-casein mixture. Staining for chloroacetate
esterase defines cells of the neutrophil granulocyte lineage and staining for the nonspecific
esterase (a-naphthylbutyrate esterase) defines cells of the monocyte/macrophage lineage.
Plasminogen ActivatorAssay.
￿
Marrow cellsthat had been separated on density gradients
were incubated with RPMI 1640 containing 3% FCS at 4 X 106 cells/ml for 24 h at 37°C
in a humid atmosphere and 5% C02 in air. Medium was harvested by centrifugation and
stored at -80'C before analysis for plasminogen activator activity.
Harvest fluids were assayed by measuring plasminogen-dependent release of soluble
radioactive fibrin degradation peptides from insoluble 25I-fibrin-coated multiwell tissue
culture plates (Linbro; Flow Laboratories, Inc., Irvine, Scotland) as previously described
(1, 18). Results were calculated in terms of urokinase units by reference to urokinase
standards assayed simultaneously. The molecular species of plasminogen activators present
in harvest fluids were identified as uPA or tPA using specific inhibitory antibodies to
these enzymes. Harvest fluid samples were incubated for 1 h at 4°C with purified rabbit
antibody and assayed for residual activity using the '25I-fibrin assay. All procedures have
previously been described in detail (19).
Caseinolytic Plaque Assay.
￿
To obtain an estimate of plasminogen activator production
by individual cells or individual clones grown in agar culture a caseinolytic plaque assay
was used. Agar culture gels containing clones were dehydrated as described. They were
immediately overlaid with a prewarmed solution of RPMI 1640 containing 0.75% agar,
and 1 .2% solution of commercial instant nonfat dry milk powder (Carnation Co., Johan-
nesburg, South Africa) and 200 ,ug/ml of purified human plasminogen. This suspension
was run between two prewarmed glass microscope slides to achieve a film of uniform
depth (^-1 mm). The preparations were allowed to set at room temperature, the top
microscope slidewas gently removed, and the gels were incubated at 37°C in a humidified
atmosphere and were inspected at intervals for the development of plaques of lysis.
Cells in suspension were washed and mixed with the agar/casein/plasminogen mixture
to give a final concentration of 2 X 106 cells/ml. This suspension was run between two
slides and processed as above.
Cells or clones of cells responsible for the production of caseinolytic plaques could be1612
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identified by dehydrating and staining the specimens for dual esterase as previously
described.
Results
Marrow samples from 11 normal subjects were fractionated by equilibrium
density centrifugation and cells from each fraction were examined to determine
the typeand rate ofplasminogen activator that they produced. Essentially similar
results were obtained in all cases.
Representative results from two experiments are presented in Fig. 1 in two
ways. In the first (AI and BI) the rate of enzyme synthesis by all of the cells in
each fraction is plotted as a function of gradient density. In the second (A2 and
B2) the rate of synthesis has been corrected for the number of cells in each
fraction and is expressed in terms of milliunits of enzyme/107 cells/24 h. It is
evident, from both graphic presentations, that the low-density cells (-1 .045-
1.065 g/cms) synthesized exclusively tPA. More mature, higher-density cells
(^-1 .07-1.085 g/cms) released a mixture of tPA and uPA. It can be seen,
moreover, from the profiles plotted in Fig. 1, A1 and B1, that the cells that
produced tPA comprised two populations. When corrected for cell number only
one peak of tPA production (density ^-1.063 g/cms) was observed, indicating
that although these cells can be divided into two populations on thebasis oftheir
density, they constituted a single population on the basis of the rate of enzyme
production per cell.
The number of cells varied markedly along the gradient with the majority of
nucleated cells fractionating at a density of -1.07 g/cms. Dashed lines indicate
fractions that were pooled because ofinadequate cell numbers for the assay (see
Materials and Methods).
A summary ofthe results of the 11 density gradient experiments is presented
in Table I. The bimodal distribution in the tPA-producing cell populations was
observed in 7 of 11 cases. In 5 of these, the 1.072-g/cms peak contained the
greater number of tPA-producing cells and the 1.063-g/cms peak the lesser
number. In the othertwo cases the 1.063-g/cms peak was greater than the 1.072-
g/cms peak .
In contrast, the uPA was produced by cells that fractionated in either a single
peak or one that had a low broad profile. The modal density of uPA-producing
cells could be estimated in five experiments since in three analyses there was a
broad profile with no obvious peak, in another experiment no uPA was present,
and in two others maximum uPA was produced by cells in the last fraction of
the gradient. The mean density for the five experiments in which this could be
estimated suggests that uPA-producing cells have a modal density of ^-1.076
g/cms. In the sample with no urokinase activity, asecond bone marrow specimen
from the same individual was tested and this also showed no uPA activity.
However, neutrophil/granulocytes from the peripheral blood of this donor did
produce uPA.
Fig. 2 a shows representative density distribution profiles for the various
myeloid progenitor cell populations and for neutrophil leucocytes (band forms
and polymorphs) obtained from normal marrow. To obtain sufficient cells forWILSON AND FRANCIS
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TABLE I
Buoyant Densities ofthe Three Major Plasminogen Activator-secreting Cell Populations
In 7 individuals the tPA-containing peak was biphasic with the first component at
￿
1.063 g/cms
and the second component at 1.072 g/cms. In four instances only one peak of tPA was obtained.
The uPA-containing enzyme peak was found at a density of 1.076 g/cms. The major (Maj) and
minor(Min) contribution to the total tPA is indicatedin parenthesis.
* Low urokinaselevels with no definite peak.
the various types of analyses a pair of matched gradients was spun on the same
rotor head and the recovered cells from one gradient were used for the CFU-
gemm cultures and cells from the second gradient were used for both CFUgm
cultures and morphological analysis. As previously established (9), CFUgemm,
the most primitive progenitor type, are the least dense with a modal density of
1.059 g/cms. Cells forming granulocyte/macrophage clones are the progeny of
CFUgemm and are a heterogeneous group of progenitor cells. These are usually
classified according to clone size with CFUgm producing clones of 40 or more
cells. Cluster-forming cells in day 7 cultures have been shown (7) largely to
represent the progeny of CFUgm. Morphological analyses in previous studies (9)
have shown that CFUgm correspond to small mononuclear cells and cluster-
forming cells correspond to the morphological categories of myeloblasts, pro-
myelocytes and myelocytes. The first and second tPA-producing cell populations
in terms of their modal densities most closely resemble CFUgm and cluster-
forming cells, respectively. Fig. 2b shows density distribution profiles for mye-
loblasts, promyelocytes, and myelocytes. The modal density for myeloblasts lies
between the modal densities for peak 1 and peak 2 tPA-producing cells. Pro-
myelocytes and myelocytes have largelyoverlapping profiles with modal densities
of 1.069 and 1.072 g/cm3, respectively. These populations may thus correspond
to the second peak of tPA, which has a modal density of 1.072 g/cms. The uPA-
producing cells with a modal density of 1 .076 g/cms (Table 1) could correspond
to neutrophil/granulocytes or the subsidiary cluster-forming cell population at
that density.
Since density-distribution profiles do not provide direct evidence for the
cellular species secreting each enzyme type, we therefore attempted to assess
Exp.
Tissue plasminogen
Peak 1
9/cm
3
activator
Peak 2
g/cm s
Urokinase
9/cm
3
1 1.0611 (Maj) 1.0694 (Min) 1.0815
2 1.0579(Maj) 1.0696 (Min) 1.0771
3 1.0643 (Min) 1.0750 (Maj) 1.0800
4 1.0621 (Min) 1.0700 (Maj) 1.0743
5 1.0610(Min) 1.0760 (Maj)
6 1.0623 (Min) 1.0695 (Maj)
7 1.0660 (Min) 1.0708 (Maj) None
8 1.0640 >_ 1.0730
9 1.0610 2:1 .0734
10 1.0630 1.0670
11 1.0672
Mean 1.0627 t 0.0026 1.0715 ± 0.0028 1.0760 ± 0.0057100
60
60
20-
b
t-PA t-PAu-PA
DENSITV (g.cm-3)
t-+ A
￿
t-+A u-+A
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FIGURE 2. (a) Representa-
tive density distribution pro-
files for the various myeloid
progenitor cell populations
and for neutrophil leucocytes
(band forms and polymorphs)
fractionated from a normal
marrow specimen. Multipo-
tent progenitors (CFUgemm,
/); granulocyte/macrophage
colony-forming cells (CFUgm,
); cluster forming cells (A);
neutrophil leucocytes ("). The
location of the two tPA- and
the uPA-producing cell popu-
lations are indicated. (b) Rep-
resentative density distribu-
tion profiles of myeloblasts (/)
promyelocytes (A) and myelo-
cytes (0) fractionated from a
normal marrow specimen.
The location of the two tPA-
and the uPA-producing cell
populations are indicated.
directly the type of plasminogen activator produced at various differentiation
stages. To do this, fractionated low-density bone marrow cells (<1 .063 g/cms)
were cultured in semisolid agar for varying periods of time. These cultures were
overlaid with an agar indicator layer containing casein, plasminogen, and inhib-
itory antibodies specific for uPA or tPA. Plaques of caseinolysis indicated plas-
minogen activation. Fig. 3 shows plasminogen-dependent caseinolysis by day 3
and day 11 clones. The plaques of lysis surrounding the clones are evident in
this figure as dark areas on an opaque background, and representative plaques
are indicated by arrows. Fig. 3, al and bl show lysis zones in a plasminogen-
containing gel by day 3 and day 11 clones, respectively . No lysis was noted in
the absence of plasminogen (Fig. 3, a2 and b2). The failure of uPA antibody to
inhibit plaque formation by day 3 clones (Fig. 3 a4) and the prevention of plaque
formation by anti-tPA antibody (Fig. 3 a3)demonstrates that theenzyme secreted
by these early progenitor cells was tPA. Inspection of the culture dishes showed
small clones of two to six cells.
The production of tPA was followed by a period of secretion of both enzyme
species from days 6-9 (data not shown), but by day 11 large neutrophil and/or3 v ,C X
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macrophage colonies were present and all of the secreted enzyme was uPA. In
contrast to the results obtained at day 3, anti-uPA antibody abolished plaque
formation (Fig. 3 b4), whereas anti-tPA antibody did not (Fig. 3 b3). This
experiment demonstrates directly the relationship between progenitor differen-
tiation stage and the species of enzyme secreted.
CFUgm differentiate both to the neutrophil/granulocyte and macrophage
lineages. We therefore examined macrophages to determine whether the differ-
entiation to this lineage is also associated with the production ofuPA. Previous
experiments have shown that macrophages do not have a clearly defined density-
distribution profile, and differentiation in the monocyte/macrophage lineage is
the exception to the usual rule associating increasing density with differentiation
(10). We therefore examined the enzyme secretion ofmacrophages derived from
low-density (<1.063 g/cm3) normal marrow cells cultured for 37 d in suspension
culture (with 5% vol/vol PHA-LCM, as the growth stimulus). After this period
of time the cultures contained abundant large macrophages; Fig. 4 shows plas-
minogen-dependent caseinolysis by these cells. Fig. 4 (al) shows plaques of lysis
in a plasminogen-containing gel. Morphological and cytochemical analysis of
these gels showed that the large nonspecific esterase (NSE)-positive cells were
centrally placed in plaques oflysis, whereas small NSE-negative cells also present
in these cultures were not observed to be surrounded by lysis plaques. No lysis
was observed in the absence ofplasminogen (Fig. 4 a2). All plaques oflysis were
inhibited by anti-uPA antibody (Fig. 4 a4), indicating that macrophages produce
uPA.
Discussion
The results showed that the secretion of tPA and uPA by hemopoietic cells
was a differentiation-linked property with tPA being produced by primitive
progenitors and uPA being secreted by more differentiated cells.
It has been shown that a variety ofhuman cells release plasminogen activators
ofeither the tPA or the uPA type (19, 20-22). Apart from the involvement of
tPA in the fibrinolytic system (23, 24), the physiologicalroleofthese two enzymes
is obscure. The enzymes are produced by a wide variety of cells, including
macrophages (25) and neutrophil polymorphonuclear leucocytes (1, 26), where
they may be involved in a number of processes including proteolysis of inflam-
matory exudates, generation ofchemotactic peptides, and processes that require
regulated local proteolysis (27). A variety ofneoplastic cells, including leukemic
cells, also secrete these enzymes (1, 19, 28-30). Enzyme secretion by leukemic
cells could reflecteither normal hemopoietic stem cell behavior or aberrant gene
expression . The results presented in this paper suggest that the former is the
case.
Tissue plasminogen activator was secretedby two populations ofbone marrow
cells, one with a mean modal density of 1.063 g/cms and the other 1.072 g/cm3.
The first population corresponds to the modal density for CFUgm. We cannot
exclude the possibility that other progenitor types also produce tPA. Several
committed progenitor populations for other hemopoietic lineages have largely
overlapping profiles with CFUgm (9). CFUgemm have a lower density than04
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CFUgm and are also far less numerous than CFUgm and would not therefore
contribute greatly to the tPA peak of density 1.063 g/cm3 . CFUgm are commit-
ted progenitor cells from the granulocyte/macrophage series operationally de-
fined in this assay system as cells producing colonies of 40 or more cells . Cells
producing clusters of 2/39 cells have a broad density profile spanning 1.072
g/cm3 (see Fig . 2a), and have been shown to represent the progeny of the
CFUgm (7). They include the recognizable neutrophil granulocyte precursor
stages of myeloblasts, promyelocytes, and myelocytes . Analysis of the density
distribution of these cells suggests that myelocytes and possibly promyelocytes
are responsible for the second tPA peak (see Fig . 2b) .
The contribution to the total tPA by the two populations of cells varied, the
lower density population being the major or sole source of enzyme in 6 of 11
experiments . In four experiments no enzyme was detected in the higher density
range (i.e ., 1 .072 g/cm3), all the tPA being contributed by cells of lower density
(1 .063 g/cm 3) .
This variability is unlikely to represent differences in the proportions of the
progenitor cell types . The levels of closely related progenitors have been shown
to correlate highly with each other (31) . As secretion of this enzyme is modulated
by a wide variety of agents (29, 32-36), this variability may be due to changes in
the level of enzyme secreted per cell .
Urokinase was secreted by cells with a modal densitybetween 1 .067 and 1,082
g/cm3 in five experiments (see Table 1) . The density profiles of neutrophil
granulocytes in normal marrow in Fig . 2a and promyelocytes and myelocytes in
Fig . 2b suggest that these cells were responsible for this peak of uPA . It thus
appears that either promyelocytes and myelocytes produce both types ofenzyme
or that theswitch from tPA to uPA production occurs over a range of maturation
stages .
The modal densities for uPA-secreting cells in the different experiments could
indicate variations in the level of the bone marrow granulocyte reserve, which is
labile and readily released into the blood. Thus the relative contributions of
promyelocytes, myelocytes, and neutrophils to uPA production couldvary mark-
edly .
There was considerable heterogeneity in the amount ofuPA produced, from
undetectable levels to 300 mU/107 cells/24 h. Of 11 marrows, one contained no
uPA secreting cells . This observation was confirmed in a second marrow from
the same individual . This is somewhat surprising, since bone marrow samples
contain neutrophils and peripheral blood neutrophils from this donor-secreted
uPA. The reason for the failure to demonstrate any uPA in the bone marrow
from this donor is obscure.
Thedensity distribution profiles do not provide direct evidence for the cellular
species secreting each enzyme type . We, therefore, cultured low-density marrow
cells in semisolid agar for varying periods of time . Developing clones initially
produced tPA (day 3), followed by a period of secretion of both enzyme species
(days 6-9) . By day 11 only uPA was secreted (see Fig . 3) . Macrophages derived
from low-density (<1.063 g/cm3) normal marrow cells cultured for 37 d also1620
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secreted uPA exclusively (see Fig . 4) . This demonstrates directly the relationship
between progenitor stage and species ofenzyme secreted .
The functional properties ofAML clonogenic cells have been shown (2, 3) to
have predictive value in that clone size in semisolid agar culture and the sensitivity
of clonogenic cells to gmCSA are both related to response to therapy . In normal
marrow progenitor cell populations clone size decreases and sensitivity to gmCSA
increases as cells differentiate along the granulocyte/macrophage pathway (7) .
This relationship in normal cells and the observation that the two properties
were linked in AML (3) led to the suggestion that the heterogeneity of AML
phenotypes reflects the accumulation of clonogenic cells at various stages of the
differentiation pathway and that this was related in some way to response to
therapy (5, 7) . Studies on self-renewal capacity, which is relatively high in cells
from patients with a poor prognosis, have been consistent with this hypothesis
(4). The results obtained in this study showing that early normal progenitor cells
secrete tPA, together with the previous observation (1) that patients with AML
whose cells secrete tPA alone failed to respond to induction chemotherapy,
provide additional strong evidence for this association.
Response to therapy is not associated with the morphology of AML cells,
except in the case of acute promyelocytic leukemia . Previous reports (3, 5-7)
documenting a correlation between response to therapy and AML cell pheno-
types have studied AML clonogenic cells rather than the whole AML cell
population . The present study indicates that tPA is secreted by progenitor
(clonogenic) cells; the secretion of this species of plasminogen activator may thus
indicate that an early clonogenic cell population has accumulated . Why the
accumulation of primitive precursors should determine a poor response of the
patient to chemotherapy is unclear . The accumulation of primitive cells in the
poor prognosis group might indicate a deficient intrinsic capacity of these cells
for differentiation . Alternatively, stimuli that normally induce differentiation
may be lacking . Patients deficient in gmCSA (a proliferation and differentiation
stimulus) also show a poor response to therapy (37), suggesting that both intrinsic
and extrinsic contributions to cellular differentiation may influence the response
to chemotherapy .
While it is apparent that neutrophils and macrophages may require uPA for
their role in inflammation, the reason why primitive hemopoietic cells produce
tPA is less readily apparent . The production of proteases by progenitor cells may
be necessary to provide a local proteolytic mechanism for generating biologically
active peptides . Alternatively, the proteases generated might alter cell surface
receptors to various cytokines, either on the cells secreting them or on adjacent
cells, in such a manner that would affect theirgrowth anddifferentiation capacity .
In addition, stem cells are endowed with the capacity for migration and implan-
tation in specific hemopoietic sites and this process could also require proteolytic
enzyme secretion and its modulation .
Summary
Previous studies (1) have shown that theresponse ofpatients with acute myeloid
leukemia to induction chemotherapy can be predicted by the species of plasmin-WILSON AND FRANCIS
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ogen activator that their cells secrete . Patients whose cells secreted tissue plas-
minogen activator (tPA) only failed to respond to combination chemotherapy .
Individuals whose leukemic cells display features of the early progenitor pheno-
type also respond poorly to therapy . This suggested that the two species of
plasminogen activator secreted by leukemic cells might be produced by normal
cells at distinct stages of differentiation . These results indicate that the secretion
of the two enzyme types is a differentiation-linked property of normal cells with
tPA being produced by granulocyte/macrophage progenitors and urokinase by
more differentiated cells and by mature neutrophils and macrophages .
Receivedforpublication 13 August 1986 and in revisedform 4 February 1987.
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